Intellia Therapeutics (NTLA) Financials

$9.67 +0.61 (+6.73%)

As of 05/20/2025 04:00 PM Eastern

Annual Income Statements for Intellia Therapeutics

This table shows Intellia Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-519	-481	-474
Consolidated Net Income / (Loss)	-519	-481	-474
Net Income / (Loss) Continuing Operations	-518	-477	-474
Total Pre-Tax Income	-518	-477	-474
Total Operating Income	-534	-515	-458
Total Gross Profit	58	36	52
Total Revenue	58	36	52
Operating Revenue	58	36	52
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	592	552	510
Selling, General & Admin Expense	126	116	90
Research & Development Expense	466	435	420
Other Special Charges / (Income)	0.00	0.10	-
Total Other Income / (Expense), net	16	38	-16
Interest & Investment Income	15	34	-2.54
Other Income / (Expense), net	0.73	3.64	-13
Basic Earnings per Share	($5.25)	($5.42)	($6.16)
Weighted Average Basic Shares Outstanding	98.85M	88.77M	76.97M
Diluted Earnings per Share	($5.25)	($5.42)	($6.16)
Weighted Average Diluted Shares Outstanding	98.85M	88.77M	76.97M
Weighted Average Basic & Diluted Shares Outstanding	103.52M	96.11M	88.02M

This table shows Intellia Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-114	-129	-136	-147	-107	-132	-122	-124	-103	-113	-113
Consolidated Net Income / (Loss)	-114	-129	-136	-147	-107	-132	-122	-124	-103	-113	-113
Net Income / (Loss) Continuing Operations	-114	-128	-136	-147	-107	-128	-122	-125	-103	-113	-113
Total Pre-Tax Income	-114	-128	-136	-147	-107	-128	-122	-125	-103	-113	-113
Total Operating Income	-121	-136	-145	-139	-114	-140	-131	-132	-112	-110	-106
Total Gross Profit	17	13	9.11	6.96	29	-1.92	12	14	13	14	13
Total Revenue	17	13	9.11	6.96	29	-1.92	12	14	13	14	13
Operating Revenue	17	13	9.11	6.96	29	-1.92	12	14	13	14	13
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	137	149	154	146	143	138	143	146	125	123	119
Selling, General & Admin Expense	29	32	31	32	31	29	29	31	27	24	22
Research & Development Expense	108	117	123	114	112	109	114	115	97	100	97
Total Other Income / (Expense), net	6.93	8.49	9.06	-8.14	6.57	12	9.18	7.46	8.83	-2.71	-7.70
Interest & Investment Income	6.48	7.55	9.06	-7.93	6.57	7.73	8.88	8.65	8.93	2.11	0.11
Other Income / (Expense), net	0.45	0.94	0.00	-0.21	0.00	4.63	0.30	-1.19	-0.10	-4.81	-7.81
Basic Earnings per Share	($1.10)	($1.27)	($1.34)	($1.52)	($1.12)	($1.47)	($1.38)	($1.40)	($1.17)	($1.38)	($1.49)
Weighted Average Basic Shares Outstanding	103.50M	98.85M	101.00M	96.98M	95.50M	88.77M	88.65M	88.19M	87.77M	76.97M	76.05M
Diluted Earnings per Share	($1.10)	($1.27)	($1.34)	($1.52)	($1.12)	($1.47)	($1.38)	($1.40)	($1.17)	($1.38)	($1.49)
Weighted Average Diluted Shares Outstanding	103.50M	98.85M	101.00M	96.98M	95.50M	88.77M	88.65M	88.19M	87.77M	76.97M	76.05M
Weighted Average Basic & Diluted Shares Outstanding	103.58M	103.52M	101.85M	101.58M	96.48M	96.11M	89.55M	88.49M	88.14M	88.02M	78.68M

This table details how cash moves in and out of Intellia Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-38	-295	410
Net Cash From Operating Activities	-349	-394	-333
Net Cash From Continuing Operating Activities	-349	-394	-333
Net Income / (Loss) Continuing Operations	-519	-481	-474
Consolidated Net Income / (Loss)	-519	-481	-474
Depreciation Expense	10	8.98	7.57
Amortization Expense	-18	-26	4.00
Non-Cash Adjustments To Reconcile Net Income	187	175	183
Changes in Operating Assets and Liabilities, net	-9.59	-71	-54
Net Cash From Investing Activities	126	-31	160
Net Cash From Continuing Investing Activities	126	-31	160
Purchase of Property, Plant & Equipment	-5.78	-14	-14
Acquisitions	0.00	0.00	-45
Purchase of Investments	-936	-904	-429
Sale of Property, Plant & Equipment	0.00	0.00	0.15
Sale and/or Maturity of Investments	1,067	887	648
Net Cash From Financing Activities	186	130	583
Net Cash From Continuing Financing Activities	186	130	583
Issuance of Common Equity	180	124	568
Other Financing Activities, net	5.86	6.60	15

This table details how cash moves in and out of Intellia Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-55	69	-10	-41	-55	59	-2.78	-122	-229	386	-6.91
Net Cash From Operating Activities	-149	-85	-85	-58	-121	-93	-101	-90	-109	-90	-79
Net Cash From Continuing Operating Activities	-149	-85	-85	-58	-121	-93	-101	-90	-109	-90	-79
Net Income / (Loss) Continuing Operations	-114	-129	-136	-147	-107	-132	-122	-124	-103	-113	-113
Consolidated Net Income / (Loss)	-114	-129	-136	-147	-107	-132	-122	-124	-103	-113	-113
Depreciation Expense	2.50	2.57	2.61	2.60	2.51	2.47	2.29	2.17	2.05	2.03	1.95
Amortization Expense	-2.28	-3.60	-4.28	-4.65	-5.29	-6.31	-7.92	-7.10	-4.57	-1.25	0.82
Non-Cash Adjustments To Reconcile Net Income	31	49	48	66	24	45	45	48	38	35	33
Changes in Operating Assets and Liabilities, net	-66	-4.38	4.86	25	-35	-1.75	-18	-9.69	-41	-13	-0.98
Net Cash From Investing Activities	94	152	-7.71	-24	5.90	46	80	-35	-122	-30	48
Net Cash From Continuing Investing Activities	94	152	-7.71	-24	5.90	46	80	-35	-122	-30	48
Purchase of Property, Plant & Equipment	-0.74	-0.98	-1.28	-1.01	-2.51	-1.52	-4.33	-4.30	-3.83	-3.91	-4.24
Purchase of Investments	-83	-169	-206	-301	-260	-150	-129	-243	-382	-236	-161
Sale and/or Maturity of Investments	178	322	200	278	268	197	213	213	264	210	213
Net Cash From Financing Activities	0.00	2.32	82	41	60	106	19	2.52	2.22	506	24
Net Cash From Continuing Financing Activities	0.00	2.32	82	41	60	106	19	2.52	2.22	506	24
Issuance of Common Equity	0.00	1.29	80	40	58	105	15	2.05	1.47	505	23
Other Financing Activities, net	0.00	1.03	1.70	1.18	1.96	1.00	4.38	0.47	0.76	0.53	0.72

This table presents Intellia Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	1,191	1,301	1,520
Total Current Assets	640	998	1,217
Cash & Equivalents	189	227	524
Short-Term Investments	412	685	669
Accounts Receivable	8.52	36	3.77
Prepaid Expenses	30	50	20
Plant, Property, & Equipment, net	27	33	28
Total Noncurrent Assets	524	270	275
Long-Term Investments	304	155	142
Other Noncurrent Operating Assets	219	115	133
Total Liabilities & Shareholders' Equity	1,191	1,301	1,520
Total Liabilities	319	251	285
Total Current Liabilities	111	115	127
Accounts Payable	15	7.45	5.15
Accrued Expenses	55	67	61
Current Deferred Revenue	21	22	44
Other Current Liabilities	20	19	17
Total Noncurrent Liabilities	208	136	158
Noncurrent Deferred Revenue	18	39	20
Other Noncurrent Operating Liabilities	190	97	138
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	872	1,050	1,236
Total Preferred & Common Equity	872	1,050	1,236
Total Common Equity	872	1,050	1,236
Common Stock	3,049	2,711	2,420
Retained Earnings	-2,177	-1,658	-1,177
Accumulated Other Comprehensive Income / (Loss)	0.61	-2.26	-7.46

This table presents Intellia Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	986	1,173	1,192	1,260	1,243	1,323	1,418	1,084
Total Current Assets	551	711	757	884	893	940	964	859
Cash & Equivalents	127	120	131	172	168	172	294	141
Short-Term Investments	377	538	560	619	687	736	639	687
Accounts Receivable	11	8.85	12	36	6.49	5.06	4.91	4.02
Prepaid Expenses	37	44	54	56	32	26	25	27
Plant, Property, & Equipment, net	25	29	30	32	34	33	32	27
Total Noncurrent Assets	410	434	404	343	316	350	423	199
Long-Term Investments	272	333	299	233	197	227	294	98
Other Noncurrent Operating Assets	138	100	105	110	119	124	128	101
Total Liabilities & Shareholders' Equity	986	1,173	1,192	1,260	1,243	1,323	1,418	1,084
Total Liabilities	206	211	220	223	206	218	227	260
Total Current Liabilities	113	106	105	98	92	100	103	131
Accounts Payable	12	13	19	14	3.55	12	6.89	4.38
Accrued Expenses	41	51	45	43	58	50	45	58
Current Deferred Revenue	21	22	22	22	13	22	35	55
Other Current Liabilities	39	19	19	19	17	17	16	14
Total Noncurrent Liabilities	94	105	115	126	114	119	124	128
Noncurrent Deferred Revenue	13	23	28	33	13	13	14	26
Other Noncurrent Operating Liabilities	80	82	87	92	101	106	110	103
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	780	963	971	1,036	1,037	1,105	1,191	825
Total Preferred & Common Equity	780	963	971	1,036	1,037	1,105	1,191	825
Total Common Equity	780	963	971	1,036	1,037	1,105	1,191	825
Common Stock	3,071	3,008	2,885	2,803	2,567	2,513	2,474	1,898
Retained Earnings	-2,292	-2,049	-1,913	-1,766	-1,526	-1,404	-1,280	-1,064
Accumulated Other Comprehensive Income / (Loss)	1.06	3.30	-1.16	-0.95	-3.57	-3.87	-2.68	-9.37

This table displays calculated financial ratios and metrics derived from Intellia Therapeutics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	59.55%	-30.40%	57.69%
EBITDA Growth	-2.36%	-14.89%	-80.05%
EBIT Growth	-4.28%	-8.48%	-74.67%
NOPAT Growth	-3.68%	-12.47%	-71.05%
Net Income Growth	-7.86%	-1.48%	-77.01%
EPS Growth	3.14%	12.01%	-62.96%
Operating Cash Flow Growth	11.47%	-18.24%	-48.11%
Free Cash Flow Firm Growth	19.61%	-24.98%	-174.98%
Invested Capital Growth	-105.47%	83.33%	25.57%
Revenue Q/Q Growth	34.33%	-29.92%	1.40%
EBITDA Q/Q Growth	0.85%	-4.96%	-8.40%
EBIT Q/Q Growth	0.34%	-4.14%	-7.26%
NOPAT Q/Q Growth	0.64%	-6.14%	-6.92%
Net Income Q/Q Growth	0.62%	-4.06%	-7.28%
EPS Q/Q Growth	3.67%	-1.69%	-4.58%
Operating Cash Flow Q/Q Growth	2.20%	-0.81%	-11.82%
Free Cash Flow Firm Q/Q Growth	1.57%	-4.09%	-16.91%
Invested Capital Q/Q Growth	-17.97%	-13.04%	1.50%
Profitability Metrics	-	-	-
Gross Margin	100.00%	100.00%	100.00%
EBITDA Margin	-934.85%	-1,457.14%	-882.70%
Operating Margin	-923.10%	-1,420.51%	-879.04%
EBIT Margin	-921.84%	-1,410.49%	-904.91%
Profit (Net Income) Margin	-896.77%	-1,326.51%	-909.78%
Tax Burden Percent	100.14%	100.78%	100.00%
Interest Burden Percent	97.14%	93.32%	100.54%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-54.00%	-42.10%	-41.67%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-42.82%	-36.27%	-33.51%
Return on Assets (ROA)	-41.66%	-34.11%	-33.70%
Return on Common Equity (ROCE)	-54.00%	-42.10%	-41.67%
Return on Equity Simple (ROE_SIMPLE)	-59.52%	-45.82%	-38.38%
Net Operating Profit after Tax (NOPAT)	-374	-361	-321
NOPAT Margin	-646.17%	-994.36%	-615.33%
Net Nonoperating Expense Percent (NNEP)	-14.70%	-10.03%	-12.24%
Return On Investment Capital (ROIC_SIMPLE)	-42.89%	-34.35%	-25.96%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	217.41%	321.15%	173.26%
R&D to Revenue	805.69%	1,199.36%	805.78%
Operating Expenses to Revenue	1,023.10%	1,520.79%	979.04%
Earnings before Interest and Taxes (EBIT)	-534	-512	-472
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-541	-529	-460
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.36	2.60	2.22
Price to Tangible Book Value (P/TBV)	1.36	2.60	2.22
Price to Revenue (P/Rev)	20.52	75.27	52.67
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	4.86	45.87	27.06
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-1.03	-1.05	-1.10
Leverage Ratio	1.30	1.23	1.24
Compound Leverage Factor	1.26	1.15	1.24
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	-1.22	4.29	4.58
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	5.77	8.67	9.61
Quick Ratio	5.50	8.23	9.45
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-357	-443	-355
Operating Cash Flow to CapEx	-6,038.08%	-2,817.92%	-2,485.73%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.05	0.03	0.04
Accounts Receivable Turnover	2.57	1.80	17.98
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	1.92	1.20	2.13
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	141.81	202.37	20.31
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	141.81	202.37	20.31
Capital & Investment Metrics	-	-	-
Invested Capital	-34	-17	-99
Invested Capital Turnover	-2.29	-0.63	-0.45
Increase / (Decrease) in Invested Capital	-17	83	34
Enterprise Value (EV)	282	1,664	1,410
Market Capitalization	1,188	2,731	2,745
Book Value per Share	$8.56	$11.73	$15.70
Tangible Book Value per Share	$8.56	$11.73	$15.70
Total Capital	872	1,050	1,236
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-906	-1,067	-1,335
Capital Expenditures (CapEx)	5.78	14	13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-73	-29	-102
Debt-free Net Working Capital (DFNWC)	529	883	1,090
Net Working Capital (NWC)	529	883	1,090
Net Nonoperating Expense (NNE)	145	120	153
Net Nonoperating Obligations (NNO)	-906	-1,067	-1,335
Total Depreciation and Amortization (D&A)	-7.53	-17	12
Debt-free, Cash-free Net Working Capital to Revenue	-125.27%	-80.22%	-196.43%
Debt-free Net Working Capital to Revenue	914.03%	2,434.52%	2,091.75%
Net Working Capital to Revenue	914.03%	2,434.52%	2,091.75%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($5.25)	($5.42)	($6.16)
Adjusted Weighted Average Basic Shares Outstanding	98.85M	88.77M	76.97M
Adjusted Diluted Earnings per Share	($5.25)	($5.42)	($6.16)
Adjusted Weighted Average Diluted Shares Outstanding	98.85M	88.77M	76.97M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	103.52M	96.11M	88.02M
Normalized Net Operating Profit after Tax (NOPAT)	-374	-361	-321
Normalized NOPAT Margin	-646.17%	-994.17%	-615.33%
Pre Tax Income Margin	-895.50%	-1,316.22%	-909.78%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Intellia Therapeutics' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-42.54%	771.57%	-24.02%	-48.82%	129.53%	-114.12%	-9.60%	-3.11%	12.03%	5.59%	84.15%
EBITDA Growth	-2.16%	1.84%	-7.33%	-2.06%	-1.92%	-21.89%	-23.41%	-45.70%	18.37%	-45.43%	-62.80%
EBIT Growth	-4.82%	-0.18%	-10.67%	-4.29%	-1.74%	-17.72%	-15.41%	-35.06%	22.48%	-38.47%	-57.84%
NOPAT Growth	-5.97%	2.46%	-10.42%	-5.07%	-1.83%	-27.07%	-24.24%	-34.62%	22.38%	-36.90%	-46.58%
Net Income Growth	-6.42%	2.47%	-11.04%	-18.83%	-4.18%	-16.54%	-7.94%	-22.85%	29.79%	-39.60%	-58.04%
EPS Growth	1.79%	13.61%	2.90%	-8.57%	4.27%	-6.52%	7.38%	-5.26%	40.31%	-24.32%	-53.61%
Operating Cash Flow Growth	-23.43%	8.45%	16.32%	35.58%	-10.37%	-3.54%	-29.11%	-6.15%	-37.00%	-64.44%	-20.77%
Free Cash Flow Firm Growth	39.93%	56.82%	51.04%	36.64%	24.36%	-62.52%	-129.78%	-959.35%	-526.44%	-5,256.36%	-219.23%
Invested Capital Growth	-61.83%	-105.47%	-96.89%	37.99%	131.84%	83.33%	85.47%	72.43%	71.23%	25.57%	3.44%
Revenue Q/Q Growth	29.15%	41.30%	30.96%	-75.96%	1,609.39%	-115.99%	-11.78%	7.84%	-7.12%	2.31%	-5.45%
EBITDA Q/Q Growth	12.02%	6.76%	-3.64%	-21.00%	17.20%	-1.95%	1.45%	-20.83%	-0.40%	-3.21%	-16.36%
EBIT Q/Q Growth	11.18%	6.40%	-3.96%	-22.15%	16.90%	-3.40%	2.03%	-19.16%	2.47%	-1.38%	-14.65%
NOPAT Q/Q Growth	11.46%	5.75%	-4.12%	-21.96%	18.51%	-6.70%	0.93%	-18.20%	-1.70%	-4.32%	-7.35%
Net Income Q/Q Growth	11.30%	5.02%	7.66%	-36.80%	18.71%	-8.13%	1.18%	-19.93%	9.07%	-0.16%	-12.47%
EPS Q/Q Growth	13.39%	5.22%	11.84%	-35.71%	23.81%	-6.52%	1.43%	-19.66%	15.22%	7.38%	-12.03%
Operating Cash Flow Q/Q Growth	-74.81%	-0.42%	-45.80%	51.78%	-29.67%	8.21%	-12.24%	17.38%	-21.65%	-14.44%	7.72%
Free Cash Flow Firm Q/Q Growth	0.99%	10.44%	19.87%	15.46%	28.81%	-1.53%	-3.70%	-0.92%	-52.95%	-43.55%	-378.07%
Invested Capital Q/Q Growth	113.23%	-17.97%	-54.75%	-258.07%	171.21%	-13.04%	51.26%	18.84%	62.71%	1.50%	7.53%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-722.54%	-1,060.62%	-1,607.32%	-2,031.06%	-403.58%	0.00%	-1,137.79%	-1,018.46%	-908.92%	-840.77%	-833.45%
Operating Margin	-726.57%	-1,059.86%	-1,588.96%	-1,998.61%	-394.00%	0.00%	-1,093.29%	-973.47%	-888.13%	-811.07%	-795.49%
EBIT Margin	-723.85%	-1,052.57%	-1,588.96%	-2,001.60%	-394.00%	0.00%	-1,090.82%	-982.23%	-888.93%	-846.53%	-854.36%
Profit (Net Income) Margin	-687.61%	-1,001.23%	-1,489.54%	-2,112.62%	-371.30%	0.00%	-1,019.21%	-909.82%	-818.07%	-835.53%	-853.53%
Tax Burden Percent	100.40%	100.73%	100.00%	99.86%	100.00%	103.63%	100.24%	99.05%	100.00%	100.54%	100.00%
Interest Burden Percent	94.62%	94.43%	93.74%	105.70%	94.24%	94.28%	93.21%	93.52%	92.03%	98.17%	99.90%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-2,843.90%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-2,840.60%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	2,815.10%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-28.80%	-54.00%	-52.23%	-49.02%	-43.60%	-42.10%	-49.66%	-45.68%	-40.14%	-41.67%	-45.76%
Cash Return on Invested Capital (CROIC)	-4,558.00%	0.00%	0.00%	0.00%	-3,484.04%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-29.38%	-48.89%	-56.66%	-73.17%	-15.48%	0.00%	-48.51%	-42.81%	-36.28%	-31.35%	-36.30%
Return on Assets (ROA)	-27.90%	-46.51%	-53.11%	-77.23%	-14.59%	0.00%	-45.33%	-39.66%	-33.39%	-30.95%	-36.27%
Return on Common Equity (ROCE)	-28.80%	-54.00%	-52.23%	-49.02%	-43.60%	-42.10%	-49.66%	-45.68%	-40.14%	-41.67%	-45.76%
Return on Equity Simple (ROE_SIMPLE)	-67.43%	0.00%	-54.26%	-52.40%	-46.86%	0.00%	-44.58%	-41.04%	-36.15%	0.00%	-53.58%
Net Operating Profit after Tax (NOPAT)	-85	-96	-101	-97	-80	-98	-92	-93	-78	-77	-74
NOPAT Margin	-508.60%	-741.91%	-1,112.27%	-1,399.02%	-275.80%	0.00%	-765.30%	-681.43%	-621.69%	-567.75%	-556.84%
Net Nonoperating Expense Percent (NNEP)	-3.31%	-3.38%	-3.36%	-4.67%	-2.45%	-2.85%	-3.08%	-2.92%	-2.14%	-2.90%	-3.68%
Return On Investment Capital (ROIC_SIMPLE)	-10.84%	-10.95%	-	-	-	-9.32%	-	-	-	-6.24%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	174.46%	252.01%	334.77%	456.99%	107.45%	0.00%	245.19%	225.48%	217.74%	174.07%	166.93%
R&D to Revenue	652.11%	907.85%	1,354.19%	1,641.61%	386.55%	0.00%	948.10%	847.99%	770.40%	737.01%	728.56%
Operating Expenses to Revenue	826.57%	1,159.86%	1,688.96%	2,098.61%	494.00%	0.00%	1,193.29%	1,073.47%	988.13%	909.24%	895.49%
Earnings before Interest and Taxes (EBIT)	-120	-136	-145	-139	-114	-135	-131	-134	-112	-115	-113
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-120	-137	-146	-141	-117	-139	-136	-138	-115	-114	-111
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.94	1.36	2.17	2.22	2.38	2.60	2.70	3.25	2.75	2.22	5.16
Price to Tangible Book Value (P/TBV)	0.94	1.36	2.17	2.22	2.38	2.60	2.70	3.25	2.75	2.22	5.16
Price to Revenue (P/Rev)	16.15	20.52	48.45	46.97	46.83	75.27	54.05	67.77	61.35	52.67	82.75
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	122.02	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	4.86	25.44	25.44	27.36	45.87	33.73	46.37	38.38	27.06	64.74
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.99	-1.03	-1.02	-1.02	-1.01	-1.05	-1.06	-1.07	-1.08	-1.10	-1.11
Leverage Ratio	1.24	1.30	1.21	1.21	1.20	1.23	1.25	1.23	1.22	1.24	1.25
Compound Leverage Factor	1.17	1.22	1.13	1.28	1.13	1.16	1.17	1.15	1.12	1.21	1.25
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	-0.93	-0.12	3.75	3.94	5.14	5.25	6.90	8.86	7.91	5.35	8.97
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.90	5.77	6.73	7.21	9.03	8.67	9.72	9.41	9.32	9.61	6.55
Quick Ratio	4.57	5.50	6.31	6.69	8.45	8.23	9.37	9.14	9.08	9.45	6.35
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-77	-78	-87	-109	-129	-181	-178	-172	-170	-111	-77
Operating Cash Flow to CapEx	-20,262.59%	-8,684.51%	-6,633.07%	-5,749.60%	-4,814.92%	-6,121.97%	-2,340.28%	-2,100.05%	-2,853.03%	-2,297.26%	-1,853.34%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.04	0.05	0.04	0.04	0.04	0.03	0.04	0.04	0.04	0.04	0.04
Accounts Receivable Turnover	1.94	2.57	5.62	5.29	2.55	1.80	9.85	13.41	15.95	17.98	15.78
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	1.59	1.92	1.38	1.45	1.65	1.20	1.71	1.80	1.93	2.13	2.21
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	187.95	141.81	65.00	69.02	143.40	202.37	37.07	27.22	22.89	20.31	23.13
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	187.95	141.81	65.00	69.02	143.40	202.37	37.07	27.22	22.89	20.31	23.13
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	4.50	-34	-29	-19	12	-17	-15	-30	-37	-99	-101
Invested Capital Turnover	5.59	-2.29	-1.98	-1.89	-4.17	-0.63	-0.90	-0.76	-0.65	-0.45	-0.50
Increase / (Decrease) in Invested Capital	-7.29	-17	-14	11	49	83	86	79	92	34	3.59
Enterprise Value (EV)	-39	282	1,096	1,169	1,439	1,664	1,746	2,459	2,053	1,410	3,328
Market Capitalization	736	1,188	2,087	2,159	2,464	2,731	2,798	3,594	3,280	2,745	4,254
Book Value per Share	$7.53	$8.56	$9.48	$10.07	$10.85	$11.73	$11.72	$12.54	$13.53	$15.70	$10.85
Tangible Book Value per Share	$7.53	$8.56	$9.48	$10.07	$10.85	$11.73	$11.72	$12.54	$13.53	$15.70	$10.85
Total Capital	780	872	963	971	1,036	1,050	1,037	1,105	1,191	1,236	825
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-775	-906	-991	-990	-1,024	-1,067	-1,052	-1,135	-1,228	-1,335	-926
Capital Expenditures (CapEx)	0.74	0.98	1.28	1.01	2.51	1.52	4.33	4.30	3.83	3.91	4.24
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-65	-73	-53	-39	-5.16	-29	-53	-68	-73	-102	-100
Debt-free Net Working Capital (DFNWC)	439	529	605	652	786	883	802	840	860	1,090	728
Net Working Capital (NWC)	439	529	605	652	786	883	802	840	860	1,090	728
Net Nonoperating Expense (NNE)	30	33	34	50	28	34	30	31	25	36	39
Net Nonoperating Obligations (NNO)	-775	-906	-991	-990	-1,024	-1,067	-1,052	-1,135	-1,228	-1,335	-926
Total Depreciation and Amortization (D&A)	0.22	-1.04	-1.67	-2.05	-2.77	-3.84	-5.63	-4.93	-2.52	0.78	2.77
Debt-free, Cash-free Net Working Capital to Revenue	-142.53%	-125.27%	-122.77%	-84.73%	-9.81%	-80.22%	-102.86%	-128.79%	-136.99%	-196.43%	-195.28%
Debt-free Net Working Capital to Revenue	962.93%	914.03%	1,404.68%	1,418.67%	1,494.43%	2,434.52%	1,548.42%	1,583.30%	1,608.77%	2,091.75%	1,415.93%
Net Working Capital to Revenue	962.93%	914.03%	1,404.68%	1,418.67%	1,494.43%	2,434.52%	1,548.42%	1,583.30%	1,608.77%	2,091.75%	1,415.93%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.10)	($1.27)	($1.34)	($1.52)	($1.12)	($1.47)	($1.38)	($1.40)	($1.17)	($1.38)	($1.49)
Adjusted Weighted Average Basic Shares Outstanding	103.50M	98.85M	101.00M	96.98M	95.50M	88.77M	88.65M	88.19M	87.77M	76.97M	76.05M
Adjusted Diluted Earnings per Share	($1.10)	($1.27)	($1.34)	($1.52)	($1.12)	($1.47)	($1.38)	($1.40)	($1.17)	($1.38)	($1.49)
Adjusted Weighted Average Diluted Shares Outstanding	103.50M	98.85M	101.00M	96.98M	95.50M	88.77M	88.65M	88.19M	87.77M	76.97M	76.05M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	103.58M	103.52M	101.85M	101.58M	96.48M	96.11M	89.55M	88.49M	88.14M	88.02M	78.68M
Normalized Net Operating Profit after Tax (NOPAT)	-85	-96	-101	-97	-80	-98	-92	-93	-78	-77	-74
Normalized NOPAT Margin	-508.60%	-741.91%	-1,112.27%	-1,399.02%	-275.80%	0.00%	-765.30%	-681.43%	-621.69%	-567.75%	-556.84%
Pre Tax Income Margin	-684.89%	-993.93%	-1,489.54%	-2,115.61%	-371.30%	0.00%	-1,016.74%	-918.57%	-818.07%	-831.02%	-853.53%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Intellia Therapeutics' Financials

When does Intellia Therapeutics's financial year end?

According to the most recent income statement we have on file, Intellia Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Intellia Therapeutics' net income changed over the last 2 years?

Intellia Therapeutics' net income appears to be on an upward trend, with a most recent value of -$519.02 million in 2024, rising from -$474.19 million in 2022. The previous period was -$481.19 million in 2023. Find out what analysts predict for Intellia Therapeutics in the coming months.

What is Intellia Therapeutics's operating income?

Intellia Therapeutics's total operating income in 2024 was -$534.26 million, based on the following breakdown:

Total Gross Profit: $57.88 million
Total Operating Expenses: $592.14 million

How has Intellia Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Intellia Therapeutics' total revenue changed from $52.12 million in 2022 to $57.88 million in 2024, a change of 11.0%.

How much debt does Intellia Therapeutics have?

Intellia Therapeutics' total liabilities were at $319.06 million at the end of 2024, a 27.2% increase from 2023, and a 12.1% increase since 2022.

How much cash does Intellia Therapeutics have?

In the past 2 years, Intellia Therapeutics' cash and equivalents has ranged from $189.18 million in 2024 to $523.51 million in 2022, and is currently $189.18 million as of their latest financial filing in 2024.

How has Intellia Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Intellia Therapeutics' book value per share changed from 15.70 in 2022 to 8.56 in 2024, a change of -45.5%.

Related Companies

This page (NASDAQ:NTLA) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intellia Therapeutics (NTLA) Financials

Frequently Asked Questions About Intellia Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intellia Therapeutics (NTLA) Financials

Annual Income Statements for Intellia Therapeutics

Quarterly Income Statements for Intellia Therapeutics

Annual Cash Flow Statements for Intellia Therapeutics

Quarterly Cash Flow Statements for Intellia Therapeutics

Annual Balance Sheets for Intellia Therapeutics

Quarterly Balance Sheets for Intellia Therapeutics

Annual Metrics And Ratios for Intellia Therapeutics

Quarterly Metrics And Ratios for Intellia Therapeutics

Frequently Asked Questions About Intellia Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools